Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccines against tuberculosis.

D B Lowrie1

  • 1National Institute for Medical Research, Ridgeway, Mill Hill, London, NW7 1AA, UK. dlowrie@nimr.mrc.ac.uk

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Involvement of methylated HBHA expressed from Mycobacterium smegmatis in an IFN-γ release assay to aid discrimination between latent infection and active tuberculosis in BCG-vaccinated populations.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2017
Same author

Repeated use of qiagen columns in large-scale preparation of plasmid DNA.

Methods in molecular medicine·2011
Same author

Progress towards a new tuberculosis vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants.

Scandinavian journal of immunology·2003
Same author

Immune responses in tuberculosis: antibodies and CD4-CD8 lymphocytes with vascular adhesion molecules and cytokines (chemokines) cause a rapid antigen-specific cell infiltration at sites of bacillus Calmette-Guérin reinfection.

Immunology·2001
Same author

Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis.

Infection and immunity·2000
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

DNA vaccines for tuberculosis (TB) in animals are revealing how immunity works and showing promise for human use. Recent advances are key to developing practical TB vaccines.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Tuberculosis (TB) remains a significant global health challenge.
  • Understanding protective immunity is crucial for effective vaccine development.
  • Current TB vaccines have limitations in efficacy.

Purpose of the Study:

  • To review recent advances in DNA vaccine technology for tuberculosis.
  • To explore the immunological mechanisms elucidated by DNA vaccination in animal models.
  • To assess the potential for clinical application of DNA-based TB vaccines.

Main Methods:

  • Review of current literature on DNA vaccines against tuberculosis.
  • Analysis of immunological data from preclinical studies in laboratory animals.
  • Evaluation of recent technological and conceptual advancements in vaccine development.

Related Experiment Videos

Main Results:

  • DNA vaccination in animal models has clarified key immunological pathways of protective immunity against TB.
  • Unexpectedly, these studies highlight the significant clinical potential of DNA vaccines for TB.
  • Advances in vector design and antigen selection are improving vaccine efficacy.

Conclusions:

  • DNA vaccines represent a promising platform for developing next-generation tuberculosis vaccines.
  • Further research and clinical trials are warranted to translate preclinical findings into practical human vaccines.
  • The immunological insights gained are valuable for broader vaccine strategies against infectious diseases.